Receptor-type tyrosine-protein phosphatase κ directly targets STAT3 activation for tumor suppression in nasal

Related Experiment Video

Updated: Apr 18, 2026

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

6.8K

Yun-Wen Chen1, Tianhuan Guo1, Lijun Shen1

  • 1Lymphoma Research Laboratory, Department of Pathology, Queen Mary Hospital, The University of Hong Kong, Hong Kong;

Blood
|January 24, 2015
PubMed

Insights

Receptor-type tyrosine-protein phosphatase κ (PTPRK) underexpression activates signal transducer and activator of transcription 3 (STAT3) in nasal-type natural killer/T-cell lymphoma (NKTCL). PTPRK restoration inhibits NKTCL growth and metastasis.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Genetics

Background:

  • Nasal-type natural killer/T-cell lymphoma (NKTCL) is an aggressive cancer.
  • NKTCL is characterized by 6q deletions and constitutive signal transducer and activator of transcription 3 (STAT3) activation.
  • STAT3 activation, via phosphorylation at Tyr705, drives NKTCL cell proliferation, migration, and invasion.

Purpose of the Study:

  • To investigate the role of receptor-type tyrosine-protein phosphatase κ (PTPRK) in regulating STAT3 activation in NKTCL.
  • To determine the impact of PTPRK expression on NKTCL cell behavior and patient survival.

Main Methods:

  • Assessed PTPRK expression in NKTCL cell lines and primary tumors.
  • Utilized phosphatase substrate-trapping mutant and phosphatase assays to confirm PTPRK-STAT3 interaction and dephosphorylation.
  • Investigated the effects of PTPRK restoration and knockdown on STAT3 phosphorylation and NKTCL cell growth, migration, and invasion.
  • Analyzed PTPRK gene alterations (deletion, promoter methylation) and their correlation with patient survival.

Main Results:

  • PTPRK was underexpressed in NKTCL cell lines and tumors compared to normal NK cells.
  • PTPRK expression inversely correlated with nuclear phospho-STAT3(Tyr705) levels.
  • PTPRK directly dephosphorylated STAT3 at Tyr705, inhibiting STAT3 activation.
  • PTPRK restoration suppressed NKTCL cell growth, migration, and invasion.
  • PTPRK underexpression resulted from monoallelic deletion and promoter hypermethylation, with methylation correlating with inferior survival in patients treated with specific regimens.

Conclusions:

  • PTPRK acts as a negative regulator of STAT3 in NKTCL.
  • PTPRK underexpression contributes to NKTCL pathogenesis by promoting STAT3 activation.
  • PTPRK may serve as a potential therapeutic target or prognostic biomarker in NKTCL.

More Related Videos

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo08:19

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

6.6K
Merging Absolute and Relative Quantitative PCR Data to Quantify STAT3 Splice Variant Transcripts11:19

Merging Absolute and Relative Quantitative PCR Data to Quantify STAT3 Splice Variant Transcripts

Published on: October 9, 2016

15.7K

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.5K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.5K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
14.2K
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
21.3K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
10.5K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

3.1K